This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): zoledronic acid
Description: Zometa is a bisphophonate that inihibits osteoclast-mediated bone resorption. It modulates bone metabolism by reducing bone turnover, improving bone mineralization, and increasing bone mass.
While the active ingredient of both Zometa and Aclasta/Reclast is zoledronic acid, Zometa comes in a 4mg dose given every 3-4 weeks and Aclasta is given in a 5mg dose given once a year.
Additional information available to subscribers only: